A recent systematic review by Peravali et al. showed that the combination of EGFR-TKI plus VEGF inhibitor provided a significant improvement in PFS, but not in OS or ORR, when compared to EGFR-TKI alone in stage IV NSCLC [79]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.